FibroGen Inc. has reported its first quarter 2025 financial results, reflecting a significant decline in total revenue from continuing operations to $2.7 million, compared to $25.4 million recorded in the same period in 2024. The company also reported a net loss from continuing operations of $16.8 million, or $0.16 net loss per basic and diluted share, showing an improvement from the previous year's net loss of $49.0 million, or $0.49 net loss per share. As of March 31, 2025, FibroGen's cash, cash equivalents, and accounts receivable totaled $128.4 million, with $33.8 million reported in the U.S. The company announced that the anticipated sale of FibroGen China to AstraZeneca is expected to close in the third quarter of 2025, with a total consideration of approximately $185 million. This transaction is projected to extend the company's cash runway into the second half of 2027. In addition, FibroGen has filed a Type-C meeting request with the FDA for its drug roxadustat, aimed at addressing anemia associated with lower-risk myelodysplastic syndromes (LR-MDS), with feedback expected in the third quarter of 2025. The company is also planning to initiate a Phase 2 monotherapy trial of FG-3246 for metastatic castration-resistant prostate cancer in the third quarter of 2025, with topline results from a related study anticipated in the fourth quarter of 2025.